DNL 126
Alternative Names: DNL-126; ETV:N-sulphoglucosamine sulphohydrolase; ETV:SGSH; Recombinant sulphoglucosamine sulphohydrolase - Denali TherapeuticsLatest Information Update: 11 Feb 2026
At a glance
- Originator Denali Therapeutics Inc
- Class Hydrolases; Recombinant fusion proteins
- Mechanism of Action N-sulfoglucosamine sulfohydrolase replacements
-
Orphan Drug Status
Yes - Mucopolysaccharidosis III
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Mucopolysaccharidosis III
Highest Development Phases
- Phase I/II Mucopolysaccharidosis III